Heart Failure with Preserved Ejection Fraction: Blood Pressure Control or Targeting Pathogenesis? The Role of Valsartan in the Management of Diastolic Dysfunction, Myocardial Fibrosis, and Vascular Stiffness | Ukrainian Medical Journal

Krakhmalova O.O.

Main
Publications
Heart Failure with Preserved Ejection Fraction: Blood Pressure Control or Targeting Pathogenesis? The Role of Valsartan in the Management of Diastolic Dysfunction, Myocardial Fibrosis, and Vascular Stiffness

Heart Failure with Preserved Ejection Fraction: Blood Pressure Control or Targeting Pathogenesis? The Role of Valsartan in the Management of Diastolic Dysfunction, Myocardial Fibrosis, and Vascular Stiffness

June 5, 2026

270

Therapy, General practice

Cardiology, Rheumatology

Krakhmalova O.O.

УДК: 616.12-008.331.1

DOI: 10.32471/umj.1680-3051.277323

Keywords :

diastolic dysfunction,

Difors,

Diocor,

Diocor Solo,

heart failure with preserved ejection fraction,

myocardial fibrosis,

valsartan,

vascular stiffness

Specialities :

Therapy, General practice

Cardiology, Rheumatology

Resume

Heart failure with preserved ejection fraction (HFpEF) is a complex multifactorial syndrome characterized by the combination of diastolic dysfunction, myocardial fibrosis, and increased vascular stiffness. Traditional treatment approaches focused primarily on achieving target blood pressure levels do not fully address the structural and functional myocardial changes that determine disease progression. This article reviews the pathophysiological mechanisms of HFpEF with emphasis on the role of the renin-angiotensin-aldosterone system, transforming growth factor-β, and myocardial remodeling processes. The diagnostic value of tissue Doppler imaging in assessing diastolic dysfunction is also discussed. The role of angiotensin II receptor blockers, particularly valsartan, in modulating fibrosis, remodeling, and vascular stiffness is substantiated. Clinical trial data are analyzed, and comparison with angiotensin-converting enzyme inhibitors is provided. Practical aspects of valsartan use (Diocor Solo, Difors) in patients with HFpEF are also considered.

References

1. Lam C.S., Solomon S.D. (2014)The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur. J. Heart Fail.; 16(10): 1049–55. doi: 10.1002/ejhf.159.
2. Nagueh S.F., Smiseth O.A., Appleton C.P., et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of Echocardiography. J Am Soc Echocardiogr. 2025;38(7):537-569. doi: 10.1016/j.echo.2025.03.011
3. Paulus W.J., Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013 Jul 23;62(4):263-71. doi: 10.1016/j.jacc.2013.02.092
4. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991 Jun;83(6):1849-65. doi: 10.1161/01.cir.83.6.1849
5. Borlaug B.A., Paulus W.J. (2011) Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur. Heart J., Mar; 32(6): 670–9. doi: 10.1093/eurheartj/ehq426.
6. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 4;316(23):1429-35. doi: 10.1056/NEJM198706043162301
7. The SOLVD Investigators; Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):293-302. doi: 10.1056/NEJM199108013250501
8. Cleland J.G.F., Tendera M., Adamus J., et al. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006 Oct;27(19):2338-45. doi: 10.1093/eurheartj/ehl250
9. Yusuf S., Pfeffer M.A., Swedberg K., et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003 Sep 6;362(9386):777-81. doi: 10.1016/S0140-6736(03)14285-7.
10. McDonagh T.A., Metra M., Adamo M. et al. (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J., Sep 21; 42(36): 3599–3726. doi: 10.1093/eurheartj/ehab368.
11. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317
12. Latini R., Masson S., Anand I. et al. (2002) Valsartan Heart Failure Trial Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation, 106(19): 2454–8. doi: 10.1161/01.cir.0000036747.68104.ac. PMID: 12417542.
13. Solomon S.D., Janardhanan R., Verma A. et al. (2007) Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet, Jun 23; 369(9579): 2079–87. doi: 10.1016/S0140-6736(07)60980-5.
14. Carey R.M. (2017) AT2 Receptors: Potential Therapeutic Targets for Hypertension. Am. J. Hypertens. 1; 30(4): 339–347. doi: 10.1093/ajh/hpw121. PMID: 27664954.
15. Sui X., Wei H., Wang D. (2015) Novel mechanism of cardiac protection by valsartan: synergetic roles of TGF-β1 and HIF-1α in Ang II-mediated fibrosis after myocardial infarction. J. Cell Mol. Med., 19(8): 1773–82. doi: 10.1111/jcmm.12551. Epub 2015 Mar 30. PMID: 25823960; PMCID: PMC4549028.
16. Kucukler N., Kurt I.H., Topaloglu C. et al. (2012) The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy. J. Cardiovasc. Med. (Hagerstown), 13(3): 181–6. doi: 10.2459/JCM.0b013e3283511f00.
17. Borlaug B.A., Kass D.A. (2008) Ventricular-vascular interaction in heart failure. Heart Fail Clin., 4(1): 23–36. doi: 10.1016/j.hfc.2007.10.001.
18. Duprez D.A., Weintraub H.S., Cushman W.C. et al. (2011) Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. Blood Press Monit., 16(4): 186–96. doi: 10.1097/MBP.0b013e32834944e9. PMID: 21747241.
19. Ahn Y., Kim Y., Chang K. et al. (2018) A multicenter, randomized, and double-blind phase IV clinical trial to compare the efficacy and safety of fixed-dose combinations of amlodipine orotate/valsartan 5/160 mg versus valsartan/hydrochlorothiazide 160/12.5 mg in patients with essential hypertension uncontrolled by valsartan 160 mg monotherapy. Medicine (Baltimore), Sep; 97(37): e12329. doi: 10.1097/MD.0000000000012329.
20. Kario K., Tomitani N., Kanegae H., et al. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring — The NOCTURNE Study. Circ J. 2017 Jun 23;81(7):948-957. doi: 10.1253/circj.CJ-17-0109.